Sign In
Buy SEEL
$0.400
+0 (+0%)
At Close: Feb 14, 2025
Seelos Announces Second Postponement of its Annual Meeting of Stockholders
04:05pm, Thursday, 24'th Oct 2024
NEW YORK , Oct. 24, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (OTCQB: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous syst
Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market
09:00am, Tuesday, 15'th Oct 2024
NEW YORK , Oct. 15, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for ce
Seelos Announces Postponement of its Annual Meeting of Stockholders
04:05pm, Thursday, 26'th Sep 2024
NEW YORK , Sept. 26, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous sy
Seelos Therapeutics Announces 1-for-16 Reverse Stock Split
08:00am, Wednesday, 25'th Sep 2024
NEW YORK, Sept. 25, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL ) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for
-Dosing of the SLS-002 cohort is expected to commence in 4Q2024 NEW YORK , Sept. 24, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical compan
3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers
07:45am, Monday, 08'th Jul 2024
Although psychedelic drug stocks have lost some of their earlier momentum, significant research and advancements continue under the radar. Even high-profile figures like Elon Musk reportedly use ketam
NEW YORK , May 16, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for cen
Seelos Therapeutics Announces 1-for-8 Reverse Stock Split
11:45am, Tuesday, 14'th May 2024
NEW YORK , May 14, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for cen
- Richard Pascoe appointed Chairman of the Board of Directors to spearhead the ongoing business development discussions NEW YORK , April 29, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SE
NEW YORK, March 19, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous sys
NEW YORK , Jan. 26, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervo
Company plans to continue its previously announced potential partnership discussions and expects to proceed to Phase III with SLS-002 in Adults with Major Depressive Disorder (MDD) at Imminent Risk of
Therapy's New Frontier: 3 Psychedelic Stocks for the Mental Health Revolution
01:56pm, Tuesday, 09'th Jan 2024
Though psychedelic therapies and related psychedelic stocks have fallen out of favor recently, there's still tremendous research and insight happening beneath the surface. Even Elon Musk uses ketamine
NEW YORK, Jan. 2, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous syste
Seelos Therapeutics, Inc. Releases Letter to its Stockholders
08:00am, Friday, 22'nd Dec 2023
NEW YORK , Dec. 22, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous sys
